Schonfeld Strategic Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,200	Closed	-$15.5K	–	2215
2023 Q2	$15.5K	Buy	+1,200	New	+$16.2K	﹤0.01%	1903
2021 Q4	–	Sell	-1,360	Closed	-$50K	–	2470
2021 Q3	$50K	Sell	1,360 -33,973	-96%	-$1.34M	﹤0.01%	2000
2021 Q2	$1.53M	Buy	+35,333	New	+$1.33M	0.02%	804
2019 Q1	–	Sell	-3,287	Closed	-$76K	–	1216
2018 Q4	$76K	Buy	+3,287	New	+$92.8K	﹤0.01%	1015
2018 Q3	–	Sell	-32,760	Closed	-$927K	–	994
2018 Q2	$927K	Buy	+32,760	New	+$1.17M	0.05%	406
2018 Q1	–	Sell	-6,479	Closed	-$252K	–	942
2017 Q4	$252K	Buy	+6,479	New	+$247K	0.02%	627

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's RIGL Position: Q3 2023 in Review

Schonfeld Strategic Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 1,200 shares — an estimated $15.5K sold.

Schonfeld Strategic Advisors first reported a position in RIGL in Q4 2017 and held it in 6 quarters. The position peaked at $1.53M in Q2 2021. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

Schonfeld Strategic Advisors reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 1,200 Rigel Pharmaceuticals shares in Q3 2023, an estimated $15.5K.
Schonfeld Strategic Advisors first reported a position in Rigel Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Schonfeld Strategic Advisors's Rigel Pharmaceuticals position peaked at $1.53M in Q2 2021.
106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.